Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation

Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report

Published:2024-08-12 Issue:1 Volume:1 Page:1-7
ISSN:2835-4311
Container-title:Precision Oncogenomics
language:en
Short-container-title:Precision Oncogenomics

Author:

Wessman Sandra¹²^ORCID,Mogensen Nina³⁴^ORCID,Ranta Susanna³⁴^ORCID,Saft Leonie¹²^ORCID,von Bahr Greenwood Tatiana³⁴^ORCID,Tesi Bianca⁵⁶⁷^ORCID,Díaz De Ståhl Teresita²^ORCID,Baecklund Fredrik³⁴^ORCID

Affiliation:

1. Department of Pathology, Karolinska University Hospital, Stockholm, Solna, Sweden

2. Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Solna, Sweden

3. Pediatric Oncology, Astrid Lindgren’s Children Hospital, Karolinska University Hospital, Stockholm, Solna, Sweden

4. Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Solna, Sweden

5. Department of Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Solna, Sweden

6. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Solna, Sweden

7. Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Solna, Stockholm, Sweden

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/28354311.2024.2385849

Reference31 articles.

1. A population-based study of pediatric anaplastic large cell lymphoma

2. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

3. The anaplastic lymphoma kinase in the pathogenesis of cancer

4. Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial

5. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial